OBJECTIVE: In 2016, the American Academy of Ophthalmology (AAO) changed the recommended daily dose of hydroxychloroquine (HCQ) from 6.5 mg/kg to <5 mg/kg. However, it is not clear that the lower prescribed dose of HCQ will have the same efficacy for systemic lupus erythematosus (SLE) activity or the same role in protecting against cardiovascular risk factors and thrombosis. This study was undertaken to address the frequency of HCQ retinopathy and the role of HCQ blood levels in identifying those individuals who are at a greater future risk of retinopathy. METHODS: HCQ blood levels in 537 patients with SLE from a large clinical cohort were repeatedly measured, and patients were tested for HCQ retinopathy. We assessed the risk of retinopathy according to clinical characteristics and blood levels of HCQ. RESULTS: The overall frequency of retinopathy was 4.3% (23 of 537 patients). There was a 1% risk of retinopathy in the first 5 years of HCQ treatment, 1.8% from 6 to 10 years, 3.3% from 11 to 15 years, 11.5% from 16 to 20 years, and 8.0% after 21 years of use. We found that older age (P < 0.0001), higher body mass index (P for trend = 0.0160), and longer duration of HCQ intake (P = 0.0024 and P for trend = 0.0006) were associated with a higher risk of HCQ toxicity. Higher blood levels of HCQ predicted later HCQ retinopathy (P = 0.0124 and P = 0.0340 for mean and maximum HCQ blood levels, respectively). CONCLUSION: Our data prove the utility of assessing blood levels of HCQ in the prediction of retinopathy. This would allow clinicians to either decrease the dose or increase monitoring in those patients with high HCQ blood levels.
OBJECTIVE: In 2016, the American Academy of Ophthalmology (AAO) changed the recommended daily dose of hydroxychloroquine (HCQ) from 6.5 mg/kg to <5 mg/kg. However, it is not clear that the lower prescribed dose of HCQ will have the same efficacy for systemic lupus erythematosus (SLE) activity or the same role in protecting against cardiovascular risk factors and thrombosis. This study was undertaken to address the frequency of HCQretinopathy and the role of HCQ blood levels in identifying those individuals who are at a greater future risk of retinopathy. METHODS:HCQ blood levels in 537 patients with SLE from a large clinical cohort were repeatedly measured, and patients were tested for HCQretinopathy. We assessed the risk of retinopathy according to clinical characteristics and blood levels of HCQ. RESULTS: The overall frequency of retinopathy was 4.3% (23 of 537 patients). There was a 1% risk of retinopathy in the first 5 years of HCQ treatment, 1.8% from 6 to 10 years, 3.3% from 11 to 15 years, 11.5% from 16 to 20 years, and 8.0% after 21 years of use. We found that older age (P < 0.0001), higher body mass index (P for trend = 0.0160), and longer duration of HCQ intake (P = 0.0024 and P for trend = 0.0006) were associated with a higher risk of HCQtoxicity. Higher blood levels of HCQ predicted later HCQretinopathy (P = 0.0124 and P = 0.0340 for mean and maximum HCQ blood levels, respectively). CONCLUSION: Our data prove the utility of assessing blood levels of HCQ in the prediction of retinopathy. This would allow clinicians to either decrease the dose or increase monitoring in those patients with high HCQ blood levels.
Authors: Peter M Izmirly; Nathalie Costedoat-Chalumeau; Cecilia N Pisoni; Munther A Khamashta; Mimi Y Kim; Amit Saxena; Deborah Friedman; Carolina Llanos; Jean-Charles Piette; Jill P Buyon Journal: Circulation Date: 2012-05-24 Impact factor: 29.690
Authors: Tino Munster; John P Gibbs; Danny Shen; Bruce A Baethge; Gary R Botstein; Jacques Caldwell; Fredrick Dietz; Robert Ettlinger; Harvey E Golden; Herbert Lindsley; George E McLaughlin; Larry W Moreland; W Neal Roberts; Theodore W Rooney; Bruce Rothschild; Marshall Sack; Anthony I Sebba; Michael Weisman; Kathryn E Welch; David Yocum; Daniel E Furst Journal: Arthritis Rheum Date: 2002-06
Authors: Felix Grassmann; Richard Bergholz; Julia Mändl; Herbert Jägle; Klaus Ruether; Bernhard H F Weber Journal: BMC Ophthalmol Date: 2015-03-06 Impact factor: 2.209
Authors: Jesse Y Dabit; Mehmet Hocaoglu; Kevin G Moder; Andrew J Barkmeier; Wendy M Smith; Thomas J O'Byrne; Cynthia S Crowson; Alí Duarte-García Journal: Rheumatology (Oxford) Date: 2022-08-03 Impact factor: 7.046
Authors: Maximilian F Konig; Alfred Hj Kim; Marc H Scheetz; Elizabeth R Graef; Jean W Liew; Julia Simard; Pedro M Machado; Milena Gianfrancesco; Jinoos Yazdany; Daman Langguth; Philip C Robinson Journal: Ann Rheum Dis Date: 2020-05-07 Impact factor: 19.103
Authors: Henrik Carlsson; Karin Hjorton; Sandy Abujrais; Lars Rönnblom; Torbjörn Åkerfeldt; Kim Kultima Journal: Arthritis Res Ther Date: 2020-06-01 Impact factor: 5.156
Authors: Mohammed Salah Eldin Abdelbaky; Tarek Ahmad El Mamoun; Fatma Ibrahim Mabrouk; Rasha Mohamad Hassan Journal: Egypt J Intern Med Date: 2021-06-08
Authors: Anna Broder; Wenzhu B Mowrey; Ana Valle; Mimi Kim; Candace H Feldman; Kazuki Yoshida; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2021-06-13 Impact factor: 5.178